Document is current
Any future updates will be listed below
-
Authors
Degryse, L. https://orcid.org/0000-0002-6984-0687
Teles, L. https://orcid.org/0009-0008-8941-4619
De Vleeschouwer, S. https://orcid.org/0000-0002-9576-9917
Boeckxstaens, L. https://orcid.org/0000-0001-5906-1113
Jentjens, S. https://orcid.org/0000-0003-3602-9078
Deckers, W. https://orcid.org/0000-0002-0907-7384
Lambrecht, M. https://orcid.org/0000-0002-8746-2691
Daisne, J. F. https://orcid.org/0000-0001-8584-4189
Van Laere, K. https://orcid.org/0000-0001-5200-7245
Braat, A. J. A. T. https://orcid.org/0000-0002-8824-8697
Clement, P. M.
Goffin, K. https://orcid.org/0000-0002-7453-0229
Deroose, C. M. https://orcid.org/0000-0002-6080-1577
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 6 January 2026
First Online: 17 February 2026
Declarations
:
: This retrospective study protocol was reviewed and approved by the institutional ethics committee of University Hospitals Leuven (protocol number S68916). The requirement to obtain informed consent for participation and publication was waived due to the retrospective nature of the study.
: C.M. Deroose is an employee of UZ Leuven. He is/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, IRE, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy, Telix and ITM. His institution has received travel fees from: GE Healthcare, Sirtex. P.M. Clement reports fees (to institution) from Bayer, Merck, MSD, Leo Pharma, Rakuten Medical, Takeda, Servier, and Bristol Myers Squibb (BMS); grants from AstraZeneca outside the submitted work; and fees for occasional advice to government agencies such as FAGG/EMA, and as a member of CTG/CRM in Belgium. A.J.A.T Braat is Consultant for Boston Scientific, Terumo, GE Healthcare, Telix Pharmaceuticals. Research support from Boston Scientific, Ariceum Therapeutics, Telix Pharmaceuticals and Siemens Healthineers.
